Insulin Glargine
Проводит Sanofi
Страница компанииTesting the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00174681/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 390 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 20
Критерии включения
- Subjects fulfilling all of the following criteria will be eligible for inclusion in the trial:
- Type 2 diabetes
- 24 ≤ BMI ≤ 35 kg/m2
- 7 % ≤ HbA1c ≤ 8 %
- Treated with OAD for at least 2 years
- Treated with at least two oral antidiabetics including one sulphonylurea at the maximum tolerated dosages and metformin at the maximum tolerated dosages
- Not treated with a glinide or thiazolidinedione.
- Capable of performing blood glucose self-monitoring and a self-injection of insulin.
- Funduscopy within the previous year at the time of inclusion.
Критерии невключения
- Patient with any of the following criteria will not be included in the trial:
- Type 1 diabetics
- Insulin-treated type 2 diabetics or having previously received long-term insulin, or treated with a thiazolidinedione or glinide
- Fasting blood glucose < 1.20 g/l.
- Pregnancy (non-menopausal women must have a pregnancy test before the inclusion visit and effective contraception).
- Lactation.
- History of hypersensitivity to the investigational product or to drugs with similar chemical structures.
- Systemic treatment with corticosteroids irrespective of the dose and irrespective of the previous or anticipated duration of treatment.
- Treatment with another product under development in the 2 months preceding the date of inclusion in the study.
- Subject likely to receive treatments prohibited in the protocol during the trial.
- Cardiovascular, hepatic, neurological, endocrine or any other disease making it difficult to carry out the protocol or interpret the results.
- Proliferative or rapidly progressive or unstable retinopathy for at least 6 months after treatment by surgery or laser, or requiring surgery or laser in the 3 months following inclusion in the study.
- Hepatic impairment:ALT and/or AST more than three times the upper limit of normal at the initial assessment.
- Renal insufficiency:Serum creatinine >177 µmol/l (>20 mg/l) or creatinine clearance <60 ml/min.
- Previous or current history of alcohol or drug abuse.
- Mental state rendering the subject incapable of understanding the nature, objectives and possible consequences of the trial.
- Inability to undertake blood glucose self-monitoring and the injection of insulin alone.
- Subject unable to accept the restrictions of the protocol (uncooperative, unable to attend the follow-up visits and probably incapable of completing the trial).
- Subjects deprived of freedom by an administrative or judicial decision.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT00174681 · запись обновлена в реестре 11 января 2011.
Дизайн и результаты
Что измеряют — первичные конечные точки (1)
- Percentage of subjects achieving HbA1c < 7% at the end of the study.
Цель исследования
Primary objective:
The primary objective of this trial is:
* To evaluate the efficacy of initiating Lantus in combination with oral antidiabetics drugs compared to oral antidiabetic treatment optimised by enhancing hygienic and dietary measures in type 2 diabetics whose blood glucose control is acceptable but not optimal on maximum oral treatment, based on the number of patients achieving a HbA1c value \< 7% at the end of treatment.
Secondary objectives:
The secondary objectives of this trial are to compare between the two treatment groups:
* The variation in HbA1c between baseline and end of trial.
* The frequency of episodes of symptomatic hypoglycaemia (diurnal and nocturnal), severe hypoglycaemia (diurnal and nocturnal) and asymptomatic hypoglycaemia.
* Mean blood glucose levels at different times of the day.
* The variation in weight and lipid in each group between baseline and end of trial.
* The incidence of adverse events.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00174681 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.